0001493152-24-009829.txt : 20240313 0001493152-24-009829.hdr.sgml : 20240313 20240313163034 ACCESSION NUMBER: 0001493152-24-009829 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240313 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Other Events FILED AS OF DATE: 20240313 DATE AS OF CHANGE: 20240313 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MIRA PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001904286 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 853354547 STATE OF INCORPORATION: FL FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41765 FILM NUMBER: 24746367 BUSINESS ADDRESS: STREET 1: 1200 BRICKELL AVENUE STREET 2: SUITE 1950 #1183 CITY: MIAMI STATE: FL ZIP: 33131 BUSINESS PHONE: 813-369-5150 MAIL ADDRESS: STREET 1: 324 SOUTH HYDE PARK AVENUE, SUITE 350 CITY: TAMPA STATE: FL ZIP: 33606 FORMER COMPANY: FORMER CONFORMED NAME: Mira1a Therapeutics, Inc. DATE OF NAME CHANGE: 20220112 8-K 1 form8-k.htm
false 0001904286 0001904286 2024-03-13 2024-03-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 13, 2024 (March 7, 2024)

 

MIRA PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in its Charter)

 

Florida   001-41765   85-3354547

(State or Other Jurisdiction of

Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

1200 Brickell Avenue, Suite 1950 #1183

Miami, Florida

   33131
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (786) 432-9792

 

n/a

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.0001 par value per share   MIRA   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Restructuring of the Board of Directors

 

On March 9, 2024, after a series of discussions between the board of directors (the “Board”) of Mira Pharmaceuticals, Inc. (the “Company”) and senior management of the Company regarding the need to have additional scientific expertise among the members of the Board, Ms. Talhia Tuck, Mr. Brad Kroenig and Mr. Hugh McColl, each voluntarily resigned from the Board, effective immediately. This action allows the remaining members of the Board to appoint new members of the Board, as discussed below. The resignations of Ms. Tuck, Mr. Kroenig, and Mr. McColl were not the result of any disagreement with the Company on any matter relating to its operations, policies or practices.

 

Also on March 9, 2024, Dr. Chris Chapman notified the Board and senior Company management of his resignation both as Executive Chairman and as an employee of the Company, effective immediately, citing his desire to focus his time on his role as Chairman and Chief Executive Officer of Telomir Pharmaceuticals, Inc., given the recent initial public offering of that company. Dr. Chapman’s resignation was not the result of any disagreement with the Company on any matter relating to its operations, policies or practices.

 

On March 13, 2024, the remaining members of the Board (Erez Aminov and Michael Jerman) unanimously approved the appointment of (i) Mr. Aminov, the Company’s Chief Executive Officer, as Chairman of the Board and (ii) Dr. Matthew P. Del Giudice, Dr. Denil N. Shekhat and Mr. Ned MacPherson as members of the Board, to fill the vacancies on the Board occasioned by the resignations from the Board described above, for a term expiring at the Company’s 2024 annual meeting of shareholders. In due course, the new Board will designate the new members of the Audit, Compensation and Nominating and Corporate Governance Committees in conformance with the rules of the Nasdaq Stock Market.

 

The following is certain biographical information regarding Drs. Del Giudice and Shekhat and Mr. MacPherson:

 

Dr. Matthew P. Del Giudice, age 42, has practiced as a radiologist since 2014. He currently serves as a general overnight emergency radiologist at the Cleveland Clinic and as a real estate investor with Comfort Living, LLC. Prior to joining the Cleveland Clinic, from March 2021 to May 2022, Dr. Del Giudice was a general radiologist with Radiology and Imaging Specialists in Phoenix, Arizona. From July 2015 to February 2021, Dr. Del Giudice was a radiologist with Radiology Partners Phoenix, and from July 2014 to June 2015, he practiced as a musculoskeletal radiologist at the University of Arizona Health Sciences Center – Tucson. Dr. Del Giudice received his B.S. from the University of Illinois at Urbana-Champaign, his M.D. from Loyola University Stritch School of Medicine, completed his radiology residency at Loyola University Medical Center, and his musculoskeletal radiology fellowship at the University of Arizona Health Sciences Center – Tucson. Dr. Del Giudice is licensed to practice medicine in Florida and Ohio.

 

Dr. Denil N. Shekhat, age 43, has practiced as a radiologist since 2014 and currently practices at DNS Teleradiology in Wellington, Florida. Prior to starting DNS Teleradiology, Dr. Shekhat was a musculoskeletal specialist for Radiology Associates of Florida/ Radiology Partners from July 2018 to December 2023. From July 2015 to August 2018, Dr. Shekhat practiced as a general and musculoskeletal radiologist with Bethesda Radiology Associates. Dr. Shekhat received his B.A. in economics from Bowdoin College, his M.D. from the University of Tennessee Health Science Center, College of Medicine, completed his radiology residency at Baptist Memorial Hospital and his musculoskeletal radiology fellowship at the University of Arizona. Dr. Shekhat is currently licensed to practice medicine in Florida.

 

Ned MacPherson, age 36, currently serves as Chief Growth Officer for Power Digital, an industry leading digital marketing agency. Prior to joining Power Digital, from May 2016 to December 2023, he served as CEO and Head of Growth for Endrock Growth & Analytics, a company he founded and sold to Power Digital. Prior to founding Endrock Growth & Analytics, Mr. MacPherson held senior marketing and leadership positions at sunglass maker Prive Revaux (March 2018 to April 2020), curated meal company Menud (October 2014 to April 2018) and Rejuvenetics, LLC, a distributor of health and wellness products (December 2012 to March 2016). Mr. Macpherson holds a BA in Economics from Gettysburg College.

 

Resignation of Chief Science Officer

 

The Company is focused on strengthening its clinical and regulatory development expertise with a view towards a future Investigational New Drug Application (“IND”) for one of its product candidates. As part of this development, on March 7, 2024, following discussions with Company management, Adam Kaplin, M.D., Ph.D. resigned from his position as President and Chief Scientific Officer of the Company to pursue other business endeavors, effective immediately. As described in Item 8.01 below, the Company has expanded the role of an existing consultant to assist in clinical and regulatory affairs.

 

Item 8.01 Other Events

 

On March 13, 2024, the Company entered into an Amended and Restated Consulting Agreement with Angel Pharmaceutical Consulting & Technologies Ltd., an Israeli consulting firm (“APCT”). All services provided to the Company by APCT (which began in October 2023) are provided directly by Dr. Itzchak Angel, who shall be the Company’s Chief Scientific Advisor. Dr. Angel has over 30 years of experience in the pharmaceutical industry, guiding strategic drug and business development initiatives in both large and emerging companies.

 

Dr. Angel has served as Head of Pharmacology of Synthelabo (Paris, France, now Sanofi) for numerous years, where he was instrumental in the development and bringing into the market of several drugs such as Xatral (Alfuzosin), Ambien (Zolpidem) and Mizollen (Mizolastine). He formerly served as President and Chief Executive Officer of stem-cell company Accellta (Haifa, Israel) and Vice President for Research and Development at Proteologics Ltd, and at D-Pharm Biopharmaceuticals (Rehovot, Israel) where he developed several neurology compounds (stroke, Alzheimer’s and Parkinson’s Disease) into advanced clinical development and was involved in submitting numerous INDs of drugs under development. Dr. Angel is the author of more than 100 book chapters, papers, and abstracts as well as the named inventor of a number of pharmaceutical patents. Dr. Angel received his B.S. and M.Sc. in Biology from Tel-Aviv University, Israel, cum laude in 1979, and received Ph.D. cum laude from the Hamburg University, Germany in 1982.

 

As part of his consulting services, Dr. Angel shall assist the Company with (i) pharmaceutical regulatory affairs, toxicology, drug research and pre-clinical and clinical testing, (ii) outsourcing and helping the Company in managing third party vendors and (iii) working with the Company in its interactions with regulatory bodies.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  MIRA PHARMACEUTICALS, INC.
     
Date: March 13, 2024 By: /s/ Michelle Yanez
    Michelle Yanez
    Chief Financial Officer

 

 

 

 EX-101.SCH 2 mira-20240313.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 mira-20240313_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 4 mira-20240313_pre.xml XBRL PRESENTATION FILE XML 5 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Cover
Mar. 13, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 13, 2024
Entity File Number 001-41765
Entity Registrant Name MIRA PHARMACEUTICALS, INC.
Entity Central Index Key 0001904286
Entity Tax Identification Number 85-3354547
Entity Incorporation, State or Country Code FL
Entity Address, Address Line One 1200 Brickell Avenue
Entity Address, Address Line Two Suite 1950 #1183
Entity Address, City or Town Miami
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33131
City Area Code (786)
Local Phone Number 432-9792
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value per share
Trading Symbol MIRA
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://mirapharmaceuticals.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm mira-20240313.xsd mira-20240313_lab.xml mira-20240313_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "MIRA", "nsuri": "http://mirapharmaceuticals.com/20240313", "dts": { "inline": { "local": [ "form8-k.htm" ] }, "schema": { "local": [ "mira-20240313.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "mira-20240313_lab.xml" ] }, "presentationLink": { "local": [ "mira-20240313_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://mirapharmaceuticals.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-03-13", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-13", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0001493152-24-009829-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-009829-xbrl.zip M4$L#!!0 ( -"#;5B-_U2I'QP +^V + 9F]R;3@M:RYH=&WM7>M7 MXSBR_^Z_0I>]LP/G)"%/GMWL"0&ZT\TC-Z%W9N=+'\56$H%C>60Y(?SUMTJ2 M$SLDW= -#6&9,S. K4>55/K50R7YW;]NACX9,1EQ$;S_O50H_DY8X J/!_WW MO]<[C6;S]W\=..\&"HI!T2!ZOS90*MS;W!R/QX5QI2!D?[.TN[N[>8-EUDRA MO9N%YW+*;8O,Q4BJ>XV#0\SA3=DBA)L M*\_^COGH_5I#!(H%*G\Y"6'47?/7^S7%;M2F7HN;4&O3-/GN?_)Y_*=.?-K_V@.:V -:.DFU=!S M?$P:T)2D?C/PV,UG-OE:!&#;+5;+.UOW;W;K$$;[Z&OIJ\4(TSX\>D 3Y:\= M&&H6?2U_U8AHVHCTLPB!^>Z14#!6Y MY$,H<<[&I"V&-,B9!SGH7_(>2KG'1TDUCT>A3R=[)! !PW?\9@\EEDE8!OH/ M[GDLP#6!?T&I\W@([;A&WF]4&]&C'EWT4$+RQ4H>%A()@$EHF_&]S,2O$>Z] M7^,WHWQEM[9VH,7@W6:FV1_N:*%63)5*XB;PU^UH!-+Q?B_@P]!G"@>TFT[+I*A*Q MM#U!(3WA>Y9SS<0T^>V>'+#&D< M<#.>L*SF!W'(:!1+=F"7WQX429I*7F7:Q[86-VY6\K+V+?.ZS ]V,(.+^4Y@ M;0O:3/5XQ (QY,%W^OSN>,QWNJ#9Y'6:_?EA MM$MOMM+,DK=H]VX3ZAXXCO,N?"BF[I,AE7T>[!$L.OUOGZ#XY:G/^_#*A57# MY-K!NRBD0;J'?(\.N0\0_)T^=-F(WS)#$K34/?CG/TI;Q?UWFUVP4[!=^!$> MK!8+=XE/J=X\:7=O.R>=QQZN='Y/C/QL?Z^8=C MTK@X.VMV.LV+\Y5DKVS9^X-& Q[TE0ARSE&A42#E8JVZNY(L%=.HL&*T)])V M0M^.LYOXO(LF@*@J7U\?NFTCUL7[D0-V$JS"&S%DBO.(N?XQAW0 .RK MNJN0M=)NI;K2O*VZ!**'[L!$M%DHI"+K^#=.#*/@C[%($3:"/HG4KYFWL4?0 M$9C3-8TY7=/2+OZQ\?\7*YWVV+T97/QUN=/N/TCIF+ [*ABUYT'K0R@[\.AD M @2S8)%2RA"3UD[;:P=G5+H#6&XY@GTL451DW13;-J4V5G>R5U1Q)7;.O-@= M6;$S <4VZ_,(MV84!FX72]WE7X?B8UGU3^OL!TV=17VEA6H'A*K9KCNMC_7V M6;UQ_.6RV:B?=G*D>=XHO#I+:/WXAKK*P4$@&D2282$T(IV0N1B4] B'65,1 M:0PH8(C<6$U>%RT>1;L^@[Y\'YZZN!&\5ES3?X?4\Y*_'\Q?*AHR#7*XPO=I M& $YR6\ZGOA.R8>W/V)2;S#$%Y)[]#Z0HKP[D_O@J7OZF9M;7PN(?C42>9*1 MR!/N,YB^+I.+Q>_HT]'UQ[ 2!7_^E,Z:=9.2I'(1]Y-*: UMU=YD:05EJ9R1 MI4MZT[2;@:Y&D6\)EO=A\+G=JS7+._2G)&M)IVDQ*ZT=[-3RE4JM6JMNWU/. MX'_R:57<_7?B5\9*6==J([6#]_U_A"07:L D^01>>N1Q$X,0O;2IHP=N5<8@ MHT;3UN9/PM=S8]9K%->&& YYA"F5*RMNJ%@UQ0;VW@3N)4_6>K/=>1 Z'@]# M7TR87%GQS*IF(ZBB<$=*I]IV4SNU!V^.^2]WS)_6!U]@$4T9VMKZ;876\'>M MX+KG219%]L^'12]2UAY28Q#TF805L1EO_S((U%.CT1E[: 3<\5( M:;=6)/\HE78J]PR*KA3F+I#0K47STH!?+^2E& >+9^6L7_UT9827V1T+8$2)+_%P^7!X#K-7>K MXJK;VS/_,99AIL>T/&ZM'52@P]+*!4B>W&JW(Z?I$SW2DK"4>4A]5"'DLN!T*?B8_3I MWVY<_5%[)-U'&OJV0=2V=[8VEN5@S--\;&D^%8!A+63[6Y'N#ZW@5+5V6E=7 M[@_2/=]/FO:=M8-JI9S?W=XMO[H=_E>P5H"%8).N+OWK)V#Y,FFS+"0Q?Q*K M$F&9]S"S(N@SCW30PB6G-%(VH>L5Y5H\#>U7<:1X;_*8Q#<&S+UVU( 1&H)_ M$DJ..75=<4.ZS!=CG"]\B=-(=O*?28_[B-$\ L!6+/!@'I4@$1_&OJ(!$W'D M3TA$%8]Z$UW35A!=8(':S1K]0L[R;V)H1SHTF"3O>L*'SK$>^DP<(^[1WNN1 MCI4,^#VZ%6[)+1;*-1X\*H;.J=^J5;]_2*Y 9G$7)PYLB#E:K(,KT6WM/VWV M]V2\]<,9GUTA?$8#?1PYK9T7DI%6T;LH-;O;U>K^4@W]V+;X$R"+95/3YV9X M):%-(T?HP%-LI%JN&1#0JW^6@JTSK]=+VZ1QTB;E2K$ !1?;]<\NSZO@<3W! M+-\E]75.R3),Z0B?NR"K0?\,%"=H3W\QH'P:G]//O^HPB6MCRHM=;%BLXJ90^?+BJ?&I?/;Z=LIR6-+R47@6\ *]Y-\7L MO:R64M7+E]>[&_<#&U/V#6Y>TK3_M\+-R6*X:491S.1W0>=B_*467K%*]>9A M@=4? )T[%*6AI_Q?##T5EJ^NN_>#'EOVE6R(K'2X+76ZV,2_F&1>9GJGQZJU M9K'Q,)C2M_#72H2_GN"H1K7XY.D'EW@79;)?S:@[(*Y/H^CM(,T]Q&WGZ6=' M4B]Q?#N385?XZX^5.?"ZYZ;R]'.#^UR9A<,2-0P8/AYP>#(#^I=I:#Y#;E.2 MD&?5X:14[FH(6FQO'C9NW9/RIZM^[4?3/>?[25N1E;4#M#AMMGE'"??CE!%\.V,(\WZTY6$E' M)4O.Y_/9+:)WTIQFJ _GV(^0XT(A[K M\<#<.V+V0HNUQ.V;VP@U5U!5R#H.W_:^W@\MUAQ=&+H!&0OQQA),NS%!@G(W M7U[0UJ)[K::-8L!@5B_5;.'U.*!/0[OD_8%Z3-*/K= XMHVSI MOOP)2OZ80]LLA: M99U.(VMI+"Q\;V7=7$[)-1>U+5Y66U>UYE6C?'G6^.%#0TOCX\LH22^J[7O' MQ5=+,%=Z53W_7>296,K"V\A3MY6GZ7\Q=Y'_&IG*S [RM ^U_XYQ?P9J:0:U M\W%WL+]QM_O+:/NQ'MNKK& MU.O+R%]AL'=T9%,GJ=[S+ -2 FU".9%FHS"&%6WK4 S+H*,XVG M16X5I>V7'U!X&AZ:B@V=6J%8)D,0EJ%@A(]34#1 U"CZ-.>DF MHWUR[+/DMIY9T7U2#T/! X5;G_CF;CTT&UD0X6+#QRJOQ% MX)C[@G?-?<$Y0GO@"Q%*(JC!<(D1CT=NK&\]BDB7J3%C@9[9;C*SWG3=K^-S M/.17+N[KB=>_E_:UN7W&)26M["?D[T,>" AZD+P1^A0V&I# MAH?EHHSDYLA95""7U!]P2BYCW!LXDP5R**E'/DL!=/4UA?CP8]P?D#.W 7HY M9S:#1L('WX1*F!L@,8*91=]%BF&Z ];K(3 "J7PX9!X>P/$G!><2@R_4(";% MXS"1=;"&@'?(J2679!8:<$T-H&J7:5&9G(XZF4D%S]6T@%^._:=[A3\X MZ\U(DSJ W3("55) M'*9@AU4^>03PS6Q0>PXQ@$-^% ?"G7T^=*1 M7?PT:_2O\PVM44R_N;0\3F5[;HTE%G\NLQ@SO"#YZQR:QJ5R!O(\8&.G!2L' M"/W 8P^J&Y0Z @#RR7F!= ;L&A=9HN'.@=PSZK8&,$ZX+J(E"A71@H,JQ$B#<4\W#=2\]HV:Q0@"KF2=Z%[VH5!R^FP* 6)D4,T7;B& M!*H6#A3.-7 0Q( B0\:410^=O# 0OH=>$J"/X\4,T"26$Q\C+YXE MCTU?SO%>AQ%4N9E[I@T5&+AS\Q%%32%BH[W>E)$/P(G$N*VF>8C' UGD@//F MBD#'/O'-%(]D[+-I7V:;U&1GV-W0-Z!Y$4"S3Y:" F[3STYRXU:B==:[7/3Q M:]*H"4'A3;].GC+CCU!(4PM5B]+\\IPMS5^2'?LF#/<* P"B.A9M219MT?,' MO.[C@=^T@41" M^^#/&BP"J.KAUX9.^0@$,T=.3QL%O-,)W@/L7PFC3!>UGC.H;K0PH'()/YMU M1B?X>SG1/#,)'V2S6DX(1U94RE)J.TC(QO=-^B4@6H!Z:=(4&]=#]5')I/ M<:#GKP93S68SK4UT,HS!__1%=,U\IN;8M9/U)0 U+R.N]+40EB$0!>H#.1UT MY<'<) V]>:N##J72/KKH >%.URA=0W->0[:\(>%3F&F<;/]-'V8.X&NMR)? M9!=\D3Q8%Z!A817EM =P5CBRM4_%1/@TW4!'2:Y<)&\@A*]]:/ R7!Z CM6[ MF@QW0Z$51T['$^T 3TLL='FW2=T C)!AU PVDK%L!">DQW2X8,##^PRE\]"A MA+[![@>5;X(LR<22H>44Y=#>5*B)O1AP\::L7Q8^SUN\*62N/ "9]?S.D'GJ M!*+<'9UWT/EE,[D$N?B#X?+2'V--9*3@3,%4?[A=:__YN@:F$OT_7@@AT10* MM;4\ ZQZ% D777T=VK/=;BY M.S]78\QW!E4W$'T/0(@0C,:T;=2>/P>$>^= M*=[CJ-;C/LB6)B [C'-3G&@>G--OP;-6!X>8[ 8V^<)AUICA)-TDT$L,]-8+ M* @,;'[P$USK^1R*L0>:E&! D?79/-#>Q;!+%@0LBAB;4PA3F+0M.[8N:+ MY!!,-996MG(+[583RC!)<4D<0V-62XSAMR/>1W%#58_95L &&&L^TVGHQ#,O M==*5]NT=JLW=!3;I7&O6&-7 L$7FH4@;:9I$#0>-XPLM[K"Z]!Z/)1:)/ X\ MB6ZX>>3\$XRC?5(/J#\!686!HM-$17V35ZP3O72<5_A:K#-TI>C699'P; _D M3@]9W\\9,#^U162'1?>(@P9E<#F&PJ1+:=T4Q4$?#[A!\6L@!2@8,=)F(QK? M)!_01+C4Z!E*T)0P0L4-/9D4T6.(WD+"Y1D+8L]9OW"5,(-IS-^D8FG'[&&U MV54\ H@U+( 7@2/E8;(<[\;H;6"PVV 9%A\#DB#"82Z;%[M@WJ^GYJM4)MJ7 ML)1N;11P4% (0QNKPD@/HOIA'4'C. NW'YA2DZ@;RWZ"DV]P\FQ[YDD0$/6# M089$EUEH>-LP?SEHCS&M9*<$]+;>(P) $-@ZX'P?5+[&7MPK<744P-H-DO5C MW^2P>!@F$*$.?L_VH4VJ*QEQH$6)LF)PA2 M_.;(=)]P.]F5F(4(TYD&2>QE;DLP1^H>'9+/%-@.<@Z:B#G2&J"EF-U@QXX3 MS$>%UK(VGDIMV'5F^0"I';OT9A@:89A"#/SJPQW=&)P?1&5,7Z8C(:/4GJ*3 MWK_'49A%\0&",6F*[!2*);/CGMGD,+G2-_"K9S=(]#:CWJ^#YZ D<'@ PR-] MS:9.9P;UA58JAL\7RYE#>SW*Y=N.W'-FR>D)-U^L.\:/DT=O^6DO!\R7;)$F MBU)[DGKQXG(+2'W(IK9LV\2*<7M++TI! M=JV!]%/E%;39WXPD93Y/ECP6[W$YG$)\O=6X3# >H,;WM>FN0R_3LP] =)J; M+GCH4(NLFU/I7=;7[@6Q=JN#3L &7KX^:\$D=OFZ+CJL377K#NBUX2Q'Q@.! MNXK0>9=]8\LVA;)U;\0C(8W[:\8'D0^C]TZE2":,FNU%K16-#<3-)FJ8'<;$ M+[Y MK\UG>&IY?^P%_"Q,8&AI)CHSCS7Q5.V",_$8^+LS"4" ?-H59+U%)8>F3R1N M->=((,:D0P/1XQO:LPWPF(R((R.(*."8VC8P>R(\P.Q6E"$M?_K.[+1@:8G# M?7EM_@5V]1E_5.^_0UD,KZ%X MVQJ].8_J0*'Z[7_5Y\"^9* %YF?=@%V2?K M?PD_A'4X-/[C&;]%5RUPUO5O%&T"MJ'WQGKZDO4DQ. M,W?NY$YHLD!+Y?'( MP=2?K;OXIZ)D_2/E/9JS8&2H^#?4I[((1?9I0U^;IL-Q$BH6;#CS3PG&H([&\:L0V+]-X(Q<.;V57STXRI53P8 M"7]D3+LH[F(V T[\5(3 "#?9LWJZS35=J7;2$,A-9B>-U<"$ 88",] &L&!* MQ2) E+A.3N%BUA4-]4^=[=9%V,/@ $PY1@SPIT[7H$--&IHT?3/Q33/E7.)(B)6$4BEFX2-P1]$4YW]1-O/S!NJ'G.I:>= MW F!)>9A[KO--H/6Q@(!IJ_Y<.::X,I\.4&:S&[KYZ8XZPKO%UL=SWF F2!-YR< M.[S/E2I)OG7F0@0/=^9=JH/&RIQMP$\?H;,.3K0-8 JC)[H,-&0/G&^M1+0) M:0N@/1RCK:J;,X8C$.^]HCM:7O,EH?=M[A==P AIZ;) M:GVLM\_JC>,OE\U&_;0#_L1YH_"2/REJY:JFKV'X%9/VHQ167CJ!U>TGIO#E MB,VCAL7 B=_3A&1#VH\Q-X])Y^%D[ULD/=XML(^\4;\9;9K1Y2YXAZ":_D,# M=JM3?5Z_<#W>,G_]5"4"HFFQ0O(F'V]4)53I6+PFY&1ZB5D2CW^UMWM^,PA4 MV2<7H8Z&[9G/P;[%A+X9$UKUL(V5C%E,"HC?[ IO C*^.5!#_^#_ 5!+ P04 M " #0@VU8!/P$[B\# $# $0 &UI'-DM5;; M"C&7!!&&T:CE4R$%"7>81.FL;#T+P;MKI= ]W>O'V# MU--X9YJH0\#WZJC-7+-+Q^P:?<$!U-$GH,"Q9/P:/6(_TA;6(3YPU&)!Z(,$ MM9%XJJ,+JUS"R#2/T'T$ZC'^,.CFNE,I0U&W[?E\;E$VPW/&7X3ELN XP:'$ M,A*Y6FE12I_CZ'TBW)QE_K@C+X%UL1B? MV.52R;&?^[UAC#,28'WA$_JR"^[4:C4[WLV@!>1BQ/U,NF+K[1$6D"NK77( M3ZB0F+H;>$_FA'7PA9UL;D#)3F@U@9(,ZL$63H!K3=C,5AL*7ZYDP$B8$XS# M'#S&8A2+IAL;8,%E$:B,VR!3+D,0.Z')U@:AWQW :2F$] ZGX3H=(X7CCK7TPI M4VVN9BVU:%L8$M7'N4&9=-WKG/GP726$]$+-V:O>-,YN,75M&(AX32-9KNEF MRAZ,"25Q%.F(.GW:VZ0 M]B,,9/_#S'T\.C5S10'_/Z;(%H;[T#6;?"!Z MS(VE#E#TFYGQ3&TRG;)9<:R%\%:1GA+$Z@1."R+CG1'$GLM^EW^Q#ZX7NH4J MQSK=\]$XZ'0GQP9?BLQR=@CKGYB_B"&6.2F(C7)ZDMM:0HN6357'BK,_G->8 M\;LXJPE<%E')EZSFO&JN?@^,*D>&3(NC_A7/=GM$%1>>[6J!A)VIJ M^0=02P,$% @ T(-M6,G4=:?]"@ @(8 !4 !M:7)A+3(P,C0P,S$S M7VQA8BYX;6S-G5UOX[@5AN\+]#]PW9L6&,>)@Q9(=F87&4^R,#:;9&//;-M% ML: EQA%"DP$E)_:_+RF)LD3Q2$J*DIR+&8_X'NJE^)BDOHX__KC;4/1"1)IP M]FETT_/)Y/7U]8CQ%_S*Q5-Z%/'- ML H7&ZX_%.$?Z0)>SI7?ZUP2I \7BP]WZ7)IY':;[G;U],C+M:3 MZ?'QR>2?OUPOHD>RP>.$J>,6D9&.4K78XD[.SLXF>:F6MI2[E:!Z'Z<3;:>J M698F'?J:DS0Y3W-[USS"6=[MO;M!H$+];ZQE8[5I?#(=GYX<[=)XI ]^?@0% MI^2>/*"\F>?9_EFBE":*A%&Y[5&0![L9*L1$Q4\86>.,Q&I'9VI')_]0._I+ MN?D:KP@=(:64?(#M.FO4509-7)N](R+A\25[GVLSVI-]^=T1V?_0@'J\\R8L M>8;IN\S7(YW;OB'O.^*'./='6H[SY'U'NA;Y?[&=M2V_^?#:CRM5&Z_EIX9% MLLOD!$9B;5)5T3$"YWO()X:R[JIV'C7JI6HTYZ+==C4SYG6F)#I:\Y=)3!)9 M]_14?1BK#WFSY7_^F'&Y$KA8I9G 4:9KRIOQ:60IGYB6E/)":%]81#V-*Q63 MB,NIZ3D;T^(P%N$/@F^LNRU;S2V%?]!5%5\<%KD+P&A#)DC*MR(B;^J5NEOH M*)6.-E0JU)**L/'7Q>B'7(-^UZK_?)P<:G'0T7()M-T0EBUEC986-(M==;/- ME.[E>ED0G6PQ9/:QEB"E<=S!%W+'L=KY%<5KBWVCW%476VWI/FX4!M')-D=F M+U<:I$2^NOD+22.1/*OE?%<[&C+GG6XQV>K[FB8L!-K&8!)J6D\#^SU9)VIJ M41;4^2U1&SN&,4#O>NCOM&W.!59Q$- ,<0C.%O4@5$5YXNB"L2VF]^29BRY\ MFC+7U-A,FK#4-4$Q8C$&HE%H42'V1,2O6WG&3@3=]T+14KKF K!JHF'(@J+# M[@T$I)+[960I,$L3-8#U0M*6.C_= ,RV3CT,75"< .;@4Y)*[Y>4Q2.A5-T/ MP*Q_0+&)7=,"&S9Y:2N#(@:T!S*31Z R)!QL+E_4ZEPNDP8VMJ;W"4_+=A<_ ME3A8A$R' RG*PY"*\T12[39$#T,MI6MZ *LF-X8L*&+LWD!6"CG*]?XAN63Q M($0JG1] #)MV/$I1@' TG?6A(=4^P;A*T@C3PLN5W)9V-,^B=0T(:->$I"4, M"A3('0A+$:"9R4.\ O,O@L4P7&I*/["TK-I1J60!@F)ZZ\-$Z;U ,ML*T7 - MSSBPU-E-V1ZSU?U90!<$*#WF6G=M"WD#%$\ST"7+DFROGJ>[V6Y61%@:UY:X M8@,RIYDPRX-@ 3!E,E#(D-*A0NBEY_5= I:IAQC!YI@RMP38338I:&H"(L%J M#*#AH,V?*?5"Q$R.3 +3.8O)[F>R!]O5TKEE K#9A,(0!42%W1F 12E&N1I) MN1J:(M=(L&9+3)AJD*" [ &D!'J4:+^ MDN)Y\!Y*0+U;6'IL-YD!Q &AT^T0($@&H6:43Y#F+.+BF=<>=YCQK1P ]S,> MPRN4GBBW4 UJ0A.MSI" !OB$\"L$?JA>"8%3UX!4C5X(>XBCN6!2LM_ MKA-&3L#V6[5NZ>JPVV3*(@R()-@=P$^I_* _(!6#;EDHT$S?T-2I?VBF0Z&9 M!@W-]#W0+%]Y(-""N6_-7V<#:H M](),VZH5F(,L/%Q:WOI@40%J/:-"?&*2+ZQNQ9W@+PF+X"4S)/<"#&#:2HVA M#0\=N\$^?JH%L8[S.M84B_+>+XF6^1EEFB;M0TRA"0^2IK'>P:50^T3BCJ<9 MIO].GCM/Q.UB+WA8#5LA:2C#0\5FKP^8(@;)(!\GUB6NZH:&]54RH]S=*\ 6 M6X=7@&N%04!@<]1^!;BX>E*(7'>S8E00#(P(S6)GG6PQ5?5QK2R,+FX;:O5P M_KV6&A]?9)7=A=X]<@8_(-"6N.IIR)SN;;,\B!X'3)F]GLM0KO-T-5YEF$CM MPW>MS-G,;MJI)G)=$$3OFFY:T[0N=]R;OXDDDWN>\[G)DDE%K4%#O&8L%I$B59PM:_R)-/D6!;JVPB5T# !C4-;440 M*("V3 X.0J25CB&X$T1!2&1'Y"\!JL1"XO;AP3K;=XE=0=%O6,,!*X. I->> M"8L,&$>U"%2$H#S&+S;S--T2\29X+"&>$ +- R"U]"'B!)GLA:H(],G6@D1; M.3_N3Z:K99)1V\EE6^)L3@+,53.241X$&X IDX6\#/$'=#+]Z^IO2$O+W^AK3T/^Y2YZE*8(\$*"7>9ZZ+>9-(?_NB8(!#J, MM4Y*2BG26A\O)!RFK'7_(F#M;1&P[ED$K$-K=%BA Y+MVN M:++&0'+"3K5K*#HLFWQ8I$&A OL#QXPJ!!UB7&>TS%.D;IUN6 M89&_2RYL(Q.@P/9"$96G+T-24H>R3HLOP9 MNGHF^*(>7[\T$D7JA8AB5DBD Z MQ#$UMY)A43^/RTW,,[(!WW;H#W%%T%#SFJ,^?1 T#31I,I6'-4^N\T"D(GUF M,ZHGMX>7> V1XY6QQ:"Q,*XI@F $M 4MB^N_%> G=]YV19/HBG(,7V5I:!QG MS&O;,Y+E'00!$=!V!:7(RX4H5WKI_\^8/8GM&- XR9#1T1 Z VP"=UPR"-1'OH!%<&H%NWI_"P]9 $D M\>?]/7D@0KUWL"2[[+/%;W4*G>BFJ5X!6 MZAFQL@KTNZH$Y;78?K^\ONE:?I*;]2;YUPJG1&[Y+U!+ P04 " #0@VU8 M2/NJ_5X' #K5P %0 &UIC(:,\.8_>R[@]$E/Y)OI,4GH>?:"" M*F*D>A-])3QS1^20<:JB@4P7G!IJOR@:/H]>G_1.2=1N ^K]2D4BU9?[T;;> MN3$+?=[I+)?+$R&?R%*J1WT2RQ16X=@0D^EM;:>KT\U/4?R",_%X[GY-B*:1 MY27T^4JSRY9K=]/LLG\BU:S3.SWM=O[^=#..YS0E;28^4[FQKMM^R@/V.)YJ=Z]R]&QD3DX>]MIG(:^'^:Y=F M;7>HW>VU^]V3E4Y:)?R!Z[CK/K M#*3MF];IO(:YHM/+EK.W#?5>G?:[?=?,KWM&9KVP?50SU\5:46?/A86BF@J3 MJ[ZQ!_:*T)6Q/8LF946N_?_AI&'&E=MTH6[4=OTM2VVS]F-AN?&I](K+>,\1 M[N(B#U27?3RGKVE\,I-/G80R&X5>WWUP2 H<]I_O>4-7$VT4B4U9$R<3RO/Z MOUN; Y-. UZ5)!YLC=5.[5L<^K0;ORL51U(E5%G695U$Q7M1.^ZN&XO.@BA; M43N>,[X-^%3)U$=G0T)Z'-T%99MHAN:5;3]Q/@PYF57C/# !\NQB *U4@T7T M/=6Q8@O'I0;LGB60;P^5;X6VAC&7Y\X]G3'GKW/%782I.Q@>%SQ%@.#[F"-% M4"U2!*Z$R B_IPNI:L#O6P)YO\+D7:4-"?-?&5&&*KZ&D#XR!L)^C0G;HQ") M]X,B0C/'!P+\V!I(_#?4&P^/1B3DXSGEW"5V1(!Z>94]$/OOF-C].E\ ^.LG M=WVWEQ8X^YTB0/Q_O!3\1VJ1(G!'%9.)O:0K /LC8R#U,TSJ'H6HO*]% J6] M-07G/_BP#^0AH1XR'1->>#2TQW08=X4Y%#E*SEDK$Q7[/Y0H,/0=8RARE#2T M1F+#P >94GO.!$<5OS44.4H"6B>R8>;7PC"S=C,!G[-T\N/!Z3[K8RLH8Y2D MTR<*A6WYI$$8-\$1XGMH"66,DFN&Q*%P'E@]BO"12.CJ(UV'0!^90DFCY)A! M>2BH[Q1+B5J/65P_:!S;0F&C9)9A@2BT'\AJE%A5;,J**<)ZZ-XB4/8H:25( M+DH(1B*6:B%W'A8SI*,$Y2I)+"Z]^7/#!.V& M0E%I#IXCP@M 0.8+P=Y['O8>'#M*'EHK\X5@[S\/>Q^.'247K96)B7U@/]ZJ M![GTS$![C:'(47+1&HF8P/,KS:VZ4_*)%2NEZJ@?E8"B1TQ1PV)1.WQQD8?T M]M(2RALQ7:T6A\GY3FI#^+]L47VCA6TIT8 +E MBY*K5LII&JF+L*+$WWWW+:! 41+0*C$-\[R1;NYC+D7P>>RQ%90K2B;I$]7T MP.O6%&OOJ;_S-7@%&\JP>BBC88S?%#/6@X%,TTQLGM%X9L4\IE"\*.E?4%[# MJ,>2LY@9)F:?[!VB8H17HBS2UM]WY.BZWZ4#=3J>^ MD3=D#R6.DNO5"\4E/](ZH^JY_"M*0:. DO9!13<]SM XL\/>NMN;/+@=,YY1 MYL@*RAHEY?.):ICM9_F@B-O!-UZG$\G]VT,J#:&$41*\@+2&(>_Y48WWP 0* M%B6SJY2#-"9^;8BY+Q^40AL2W6 MAMLSZG;"V8SX=Y(%"X#WV6 2#TAM>O]>ON7'[>U6:>['T'ZHQNXQA0+'V2(9 MDM>3AK+XM% MS=MK3_$2CQ!Q7PDH>,1)Q+!8I/5IACJ?V1-]3PS9>!CB[RL!Y8\XH1@6B[9^ M7@WLA6IX3S=YEF@NK@V')@"(6,N.:U4AH*Y.N4 MJID=U#XHN33SS=[.$&Q/ 2ATQ)6M0:DX\%<_]I$7^]^"Y"NLP6\G0,3N%8GU MVHTX=@LIBBNY2(CR4 _90[FC;JST"VV8_*V94[5[_Y0[,[)Y6VC10WTI:!10 MTE6H:)QKZ\Y._N"E=<\.RALQ,:T2AK-G*IMP%@^Y),'[\CTS*%_$++1"%@K> M=T0\JFQAXO6=DC&E;OI$;\\V0$($K :$L3\]%DH6]'Z M-C/Y.TVM?\&'!L%RT-!@;N($"$>Z"](_-GK1Y-WZGDZI'-D4$L! A0#% @ T(-M6,G4=:?]"@ @(8 M !4 ( !IA\ &UI XML 15 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001904286 2024-03-13 2024-03-13 iso4217:USD shares iso4217:USD shares false 0001904286 8-K 2024-03-13 MIRA PHARMACEUTICALS, INC. FL 001-41765 85-3354547 1200 Brickell Avenue Suite 1950 #1183 Miami FL 33131 (786) 432-9792 false false false false Common Stock, $0.0001 par value per share MIRA NASDAQ true false